A study analysing accumulation of integrase strand transfer inhibitor resistance mutations and its association with resistance to dolutegravir in HIV-1 strains from patients failing raltegravir in Uganda
Latest Information Update: 02 Sep 2020
At a glance
- Drugs Dolutegravir (Primary) ; Elvitegravir (Primary) ; Raltegravir (Primary) ; Nucleotide reverse transcriptase inhibitors; Peptide hydrolase inhibitors
- Indications HIV-1 infections
- Focus Therapeutic Use
- 02 Sep 2020 New trial record
- 27 Aug 2020 Results published in the Nephrology Dialysis Transplantation